DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy

Keyphrases

• Prospective Evaluation 100%
• Direct-acting Antivirals 100%
• Hepatocellular Carcinoma Recurrence 100%
• Direct-acting Antiviral Therapy 100%
• Recurrence Risk 28%
• Hazard Ratio 14%
• Non-associated 14%
• Hepatocellular Carcinoma 14%
• Cirrhosis 14%
• Untreated Patients 14%
• Complete Response 14%
• Cumulative Incidence 14%
• Small Sample Size 14%
• Routine Care 14%
• Liver Cancer 14%
• Barcelona Clinic Liver Cancer 14%
• Cumulative Incidence Rates 14%
• Recurrence Events 14%
• Treatment-naïve 14%
• Hepatocellular Carcinoma Therapy 14%
• Direct-acting Antiviral Treatment 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Recurrent Disease 100%
• Liver Cell Carcinoma 100%
• Antivirus Agent 100%
• Antiviral Therapy 100%
• Liver Cancer 25%
• Prospective Study 12%
• Cancer Staging 12%
• Liver Cirrhosis 12%
• Observational Study 12%
• Recurrence Risk 12%